A novel bispecific siRNA concept: Efficient dual knockdown of <i>YAP1</i> and <i>WWTR1</i> with a single guide strand. [PDF]
Ueda K +8 more
europepmc +1 more source
Lynozyfic (Linvoseltamab): A First-in-Class Off-the-Shelf T-Cell Redirector for Refractory Multiple Myeloma. [PDF]
Ur Rehman R.
europepmc +1 more source
Radiologic Pseudoprogression Associated With a Positive Response in a Patient With Multiple Myeloma Treated With a BCMA×CD3 Bispecific Antibody: A Case Report. [PDF]
Khan AM +5 more
europepmc +1 more source
Correction: Susilo et al. Whole-Body Physiologically Based Pharmacokinetic Modeling Framework for Tissue Target Engagement of CD3 Bispecific Antibodies. <i>Pharmaceutics</i> 2025, <i>17</i>, 500. [PDF]
Susilo ME +8 more
europepmc +1 more source
Special Issue: Antibody Therapy for Hematologic Malignancies. [PDF]
Butchar JP.
europepmc +1 more source
First case report of immune checkpoint inhibitor-related pneumonitis triggered by bispecific antibody (anti-PD-L1 and anti-CTLA-4) in a patient with non-small cell lung cancer: case report. [PDF]
Sun H +5 more
europepmc +1 more source
Related searches:
Engineering bispecific antibodies
Current Opinion in Biotechnology, 1993Bispecific antibodies have immense potential as reagents and in medicine. Until recently, they were made by combining monoclonal antibodies of two different specificities in vitro, or by fusion of the corresponding hybridomas. Protein engineering now offers the chance to construct a range of small 'designer' bispecific antibodies using antibody ...
P, Holliger, G, Winter
openaire +2 more sources

